- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE HealthCare Gets FDA Nod for Next-Generation Cardiac Imaging System
The Allia IGS Pulse reportedly has the first monopolar X-ray tube geared to interventional procedures.
Designed to facilitate optimal imaging quality and dosing for complex cardiology interventional procedures, the Allia IGS Pulse has garnered 510(k) clearance from the Food and Drug Administration (FDA)
A key feature of the Allia IGS Pulse is a monopolar X-ray tube that offers quiet operation and enables steep angulation for enhanced visualization of coronary artery anatomy, according to GE HealthCare, the manufacturer of the Allia IGS Pulse.
GE HealthCare noted that other benefits of the Allia IGS Pulse include:
• a combination of X-ray peak power and reduced pulse width which reduces the motion blue that can be caused by vessels and devices;
• strong image quality for patients with a BMI greater than 30; and
• optimization of seven key imaging parameters, including focal spot shape, with the artificial intelligence (AI) leveraging image chain technology AutoRight PLUS.
Nicolas Dumonteil, M.D., an interventional cardiologist who has been using the Allia IGS Pulse in pilot operations since January 2023 at Clinique Pasteur-Toulouse in Toulouse, France, praises the imaging quality and the adaptability of the system for interventional procedures.
“As an operator of the Allia IGS Pulse system, I felt a significant and real improvement in the imaging quality, as well as a significant reduction of this noise in my daily procedures which gave me great confidence and comfort in the operating room,” noted Dr. Dumonteil. “The system is also quite adaptable and versatile to all of my daily situations and procedures — from percutaneous coronary interventions (PCIs) to other complex and structural ones.”
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
